Page 41 - Read Online

Page 10 of 11 Garg et al. Hepatoma Res 2019;5:39 I http://dx.doi.org/10.20517/2394-5079.2019.009

9. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76.
10. Ertle J, Dechene A, Sowa JP, Penndorf V, Herzer K, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in
the absence of apparent cirrhosis. Int J Cancer 2011;128:2436-43.
11. Malik SM, Gupte PA, de Vera ME, Ahmad J. Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular
carcinoma. Clin Gastroenterol Hepatol 2009;7:800-6.
12. Yang JD, Kim B, Sanderson SO, St Sauver JL, Yawn BP, et al. Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008.
Mayo Clin Proc 2012;87:9-16.
13. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, et al. Prevalence of hepatic steatosis in an urban population in
the United States: impact of ethnicity. Hepatology 2004;40:1387-95.
14. Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver
disease. World J Gastroenterol 2017;23:8263-76.
15. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, et al. The diagnosis and management of nonalcoholic fatty liver disease:
practice guidance from the American association for the study of liver diseases. Hepatology 2018;67:328-57.
16. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, et al. Cryptogenic cirrhosis: clinical characterization and risk
factors for underlying disease. Hepatology 1999;29:664-9.
17. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study.
Hepatology 2000;32:689-92.
18. Thuluvath PJ, Kantsevoy S, Thuluvath AJ, Savva Y. Is cryptogenic cirrhosis different from NASH cirrhosis? J Hepatol 2018;68:519-25.
19. Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, et al. Does nonalcoholic fatty liver disease predispose patients to
hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 2008;132:1761-6.
20. Leung C, Yeoh SW, Patrick D, Ket S, Marion K, et al. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-
alcoholic fatty liver disease. World J Gastroenterol 2015;21:1189-96.
21. Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop
without significant liver fibrosis: a pathological analysis. Hepatology 2009;49:851-9.
22. American College of Radiology. Liver Imaging and Reporting and Data System. CT/MRI LI-RADS v2017. Available from https://
www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2017. [Last accessed on Oct 15 2019]
23. Hamer OW, Aguirre DA, Casola G, Lavine JE, Woenckhaus M, et al. Fatty liver: imaging patterns and pitfalls. Radiographics
2006;26:1637-53.
24. Kodama Y, Ng CS, Wu TT, Ayers GD, Curley SA, et al. Comparison of CT methods for determining the fat content of the liver. AJR
Am J Roentgenol 2007;188:1307-12.
25. Ma X, Holalkere NS, Kambadakone RA, Mino-Kenudson M, Hahn PF, et al. Imaging-based quantification of hepatic fat: methods and
clinical applications. Radiographics 2009;29:1253-77.
26. Edge SB; American Joint Committee on Cancer. AJCC cancer staging manual. New York: Springer; 2010.
27. Byrt T, Bishop J, Carlin JB. Bias, prevalence and kappa. J Clin Epidemiol 1993;46:423-9.
28. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol
2012;56:1384-91.
29. Bralet MP, Regimbeau JM, Pineau P, Dubois S, Loas G, et al. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic
and histopathologic analysis of 80 French cases. Hepatology 2000;32:200-4.
30. Brancatelli G, Federle MP, Grazioli L, Carr BI. Hepatocellular carcinoma in noncirrhotic liver: CT, clinical, and pathologic findings in
39 U.S. residents. Radiology 2002;222:89-94.
31. Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study
of 804 North American patients. Am J Clin Pathol 1996;105:65-75.
32. Pinero F, Pages J, Marciano S, Fernandez N, Silva J, et al. Fatty liver disease, an emerging etiology of hepatocellular carcinoma in
Argentina. World J Hepatol 2018;10:41-50.
33. Trevisani F, Frigerio M, Santi V, Grignaschi A, Bernardi M. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver
Dis 2010;42:341-7.
34. Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, et al. Characteristics of patients with nonalcoholic steatohepatitis who
develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011;9:428-33; quiz e50.
35. Martin P, DiMartini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the
American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014;59:1144-65.
36. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, et al. Liver transplantation for the treatment of small hepatocellular
carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.
37. Matsui O. Imaging of multistep human hepatocarcinogenesis by CT during intra-arterial contrast injection. Intervirology 2004;47:271-6.
38. Park YN, Yang CP, Fernandez GJ, Cubukcu O, Thung SN, et al. Neoangiogenesis and sinusoidal “capillarization” in dysplastic
nodules of the liver. Am J Surg Pathol 1998;22:656-62.
39. Jang HJ, Kim TK, Khalili K, Yazdi L, Menezes R, et al. Characterization of 1-to 2-cm liver nodules detected on hcc surveillance
ultrasound according to the criteria of the American Association for the Study of Liver Disease: is quadriphasic CT necessary? AJR
Am J Roentgenol 2013;201:314-21.
40. Park MJ, Kim YK, Lee MH, Lee JH. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR
imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis. Acta Radiol 2013;54:127-36.